EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes

Kinga Szurián, Irén Csala, Dóra Marosvári, Hajnalka Rajnai, Katalin Dezső, Csaba Bödör, Violetta Piurkó, A. Matolcsy, Lilla Reiniger

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Lymph node involvement of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is characterised by the diffuse infiltration of small neoplastic lymphocytes, which is accompanied by the presence of proliferation centres (PCs) comprising prolymphocytes and paraimmunoblasts. There is increasing evidence of accumulation of various molecular alterations in the tumour cells of PCs, which may explain why extended PCs are related to a less favourable prognosis. To further characterize PCs, we compared the expression level of EZH2 protein, the overexpression of which has recently been recognized as poor prognostic factor in CLL/SLL, in the PCs and the intervening small cell areas in lymph nodes of 15 patients with CLL/SLL. We also investigated the mutational profile of EZH2 and the expression of its upstream regulators c-Myc, E2F1, pRB and miR-26a. Our results showed a significantly increased expression of EZH2 in the PCs. No EZH2 mutations were detected, however, overexpression of c-Myc, E2F1 and pRb proteins as well as reduced expression of the tumor suppressor miR-26a were demonstrated in the PCs. In summary our findings indicate that EZH2 pathway is significantly upregulated in the PCs of CLL/SLL lymph nodes, providing further evidence for the distinguished biological features of the PCs.

Original languageEnglish
Pages (from-to)161-165
Number of pages5
JournalExperimental and Molecular Pathology
Volume105
Issue number2
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Tumors
Lymph Nodes
Lymphocytes
Infiltration
Proteins
Cells
Neoplasms
Cell Proliferation
Mutation

Keywords

  • C-myc
  • CLL/SLL
  • EZH2
  • miR-26a
  • Proliferation center

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Szurián, K., Csala, I., Marosvári, D., Rajnai, H., Dezső, K., Bödör, C., ... Reiniger, L. (2018). EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes. Experimental and Molecular Pathology, 105(2), 161-165. https://doi.org/10.1016/j.yexmp.2018.07.009

EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes. / Szurián, Kinga; Csala, Irén; Marosvári, Dóra; Rajnai, Hajnalka; Dezső, Katalin; Bödör, Csaba; Piurkó, Violetta; Matolcsy, A.; Reiniger, Lilla.

In: Experimental and Molecular Pathology, Vol. 105, No. 2, 01.10.2018, p. 161-165.

Research output: Contribution to journalArticle

Szurián, K, Csala, I, Marosvári, D, Rajnai, H, Dezső, K, Bödör, C, Piurkó, V, Matolcsy, A & Reiniger, L 2018, 'EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes', Experimental and Molecular Pathology, vol. 105, no. 2, pp. 161-165. https://doi.org/10.1016/j.yexmp.2018.07.009
Szurián K, Csala I, Marosvári D, Rajnai H, Dezső K, Bödör C et al. EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes. Experimental and Molecular Pathology. 2018 Oct 1;105(2):161-165. https://doi.org/10.1016/j.yexmp.2018.07.009
Szurián, Kinga ; Csala, Irén ; Marosvári, Dóra ; Rajnai, Hajnalka ; Dezső, Katalin ; Bödör, Csaba ; Piurkó, Violetta ; Matolcsy, A. ; Reiniger, Lilla. / EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes. In: Experimental and Molecular Pathology. 2018 ; Vol. 105, No. 2. pp. 161-165.
@article{fdffca23dc694c98af2326c24f62ae7f,
title = "EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes",
abstract = "Lymph node involvement of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is characterised by the diffuse infiltration of small neoplastic lymphocytes, which is accompanied by the presence of proliferation centres (PCs) comprising prolymphocytes and paraimmunoblasts. There is increasing evidence of accumulation of various molecular alterations in the tumour cells of PCs, which may explain why extended PCs are related to a less favourable prognosis. To further characterize PCs, we compared the expression level of EZH2 protein, the overexpression of which has recently been recognized as poor prognostic factor in CLL/SLL, in the PCs and the intervening small cell areas in lymph nodes of 15 patients with CLL/SLL. We also investigated the mutational profile of EZH2 and the expression of its upstream regulators c-Myc, E2F1, pRB and miR-26a. Our results showed a significantly increased expression of EZH2 in the PCs. No EZH2 mutations were detected, however, overexpression of c-Myc, E2F1 and pRb proteins as well as reduced expression of the tumor suppressor miR-26a were demonstrated in the PCs. In summary our findings indicate that EZH2 pathway is significantly upregulated in the PCs of CLL/SLL lymph nodes, providing further evidence for the distinguished biological features of the PCs.",
keywords = "C-myc, CLL/SLL, EZH2, miR-26a, Proliferation center",
author = "Kinga Szuri{\'a}n and Ir{\'e}n Csala and D{\'o}ra Marosv{\'a}ri and Hajnalka Rajnai and Katalin Dezső and Csaba B{\"o}d{\"o}r and Violetta Piurk{\'o} and A. Matolcsy and Lilla Reiniger",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.yexmp.2018.07.009",
language = "English",
volume = "105",
pages = "161--165",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes

AU - Szurián, Kinga

AU - Csala, Irén

AU - Marosvári, Dóra

AU - Rajnai, Hajnalka

AU - Dezső, Katalin

AU - Bödör, Csaba

AU - Piurkó, Violetta

AU - Matolcsy, A.

AU - Reiniger, Lilla

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Lymph node involvement of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is characterised by the diffuse infiltration of small neoplastic lymphocytes, which is accompanied by the presence of proliferation centres (PCs) comprising prolymphocytes and paraimmunoblasts. There is increasing evidence of accumulation of various molecular alterations in the tumour cells of PCs, which may explain why extended PCs are related to a less favourable prognosis. To further characterize PCs, we compared the expression level of EZH2 protein, the overexpression of which has recently been recognized as poor prognostic factor in CLL/SLL, in the PCs and the intervening small cell areas in lymph nodes of 15 patients with CLL/SLL. We also investigated the mutational profile of EZH2 and the expression of its upstream regulators c-Myc, E2F1, pRB and miR-26a. Our results showed a significantly increased expression of EZH2 in the PCs. No EZH2 mutations were detected, however, overexpression of c-Myc, E2F1 and pRb proteins as well as reduced expression of the tumor suppressor miR-26a were demonstrated in the PCs. In summary our findings indicate that EZH2 pathway is significantly upregulated in the PCs of CLL/SLL lymph nodes, providing further evidence for the distinguished biological features of the PCs.

AB - Lymph node involvement of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is characterised by the diffuse infiltration of small neoplastic lymphocytes, which is accompanied by the presence of proliferation centres (PCs) comprising prolymphocytes and paraimmunoblasts. There is increasing evidence of accumulation of various molecular alterations in the tumour cells of PCs, which may explain why extended PCs are related to a less favourable prognosis. To further characterize PCs, we compared the expression level of EZH2 protein, the overexpression of which has recently been recognized as poor prognostic factor in CLL/SLL, in the PCs and the intervening small cell areas in lymph nodes of 15 patients with CLL/SLL. We also investigated the mutational profile of EZH2 and the expression of its upstream regulators c-Myc, E2F1, pRB and miR-26a. Our results showed a significantly increased expression of EZH2 in the PCs. No EZH2 mutations were detected, however, overexpression of c-Myc, E2F1 and pRb proteins as well as reduced expression of the tumor suppressor miR-26a were demonstrated in the PCs. In summary our findings indicate that EZH2 pathway is significantly upregulated in the PCs of CLL/SLL lymph nodes, providing further evidence for the distinguished biological features of the PCs.

KW - C-myc

KW - CLL/SLL

KW - EZH2

KW - miR-26a

KW - Proliferation center

UR - http://www.scopus.com/inward/record.url?scp=85050400636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050400636&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2018.07.009

DO - 10.1016/j.yexmp.2018.07.009

M3 - Article

C2 - 30031020

AN - SCOPUS:85050400636

VL - 105

SP - 161

EP - 165

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 2

ER -